Articles - Breast Cancer A specially curated list of peer-reviewed articles discussing the latest advancements in the diagnosis and treatment of patients living with Early Breast Cancer & Metastatic Breast Cancer. Filter by TopicAbemaciclibAdjuvant TherapyAnastrozoleBreast CancerCDK4/6CDK4/6 Inhibitor ResistanceCDK4/6 ToxicityChemotherapyClinical TrialsConferenceDalpiciclibEarly Breast CancerEndocrine TherapyGuidelinesHER2-Negative Breast CancerPalbociclibRibociclib CDK4/6 inhibitors in the treatment of metastatic breast cancer: Focus on toxicity and safety READ MORE Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer READ MORE Differences in metabolic transport and resistance mechanisms of Abemaciclib, Palbociclib, and Ribociclib READ MORE Cyclin-Dependent Kinase 4/6 Inhibitors for Treatment of Hormone Receptor–Positive, ERBB2-Negative Breast Cancer READ MORE Ribociclib and endocrine therapy as adjuvant treatment in patients with HR+/HER2- early breast cancer: Primary results from the phase III NATALEE trial READ MORE Significantly longer time to deterioration of quality of life due to CANKADO PRO-React eHealth support in HR+ HER2− metastatic breast cancer patients receiving palbociclib and endocrine therapy: primary outcome analysis of the multicenter randomized AGO-B WSG PreCycle trial READ MORE Dalpiciclib plus letrozole or anastrozole versus placebo plus letrozole or anastrozole as first-line treatment in patients with hormone receptor-positive, HER2-negative advanced breast cancer (DAWNA-2): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial READ MORE CDK4/6 inhibitor resistance in estrogen receptor positive breast cancer, a 2023 perspective READ MORE Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial READ MORE Health-related quality of life in breast cancer patients treated with CDK4/6 inhibitors: a systematic review READ MORE Emerging systemic therapy options beyond CDK4/6 inhibitors for hormone receptor-positive HER2-negative advanced breast cancer READ MORE CDK4/6 inhibitor resistance mechanisms and treatment strategies (Review) READ MORE A look at current and potential treatment approaches for hormone receptor-positive, HER2-negative early breast cancer READ MORE Targeting CDK4 and CDK6 in cancer READ MORE Targeting CDK4 and CDK6 in cancer READ MORE Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study READ MORE Mechanisms of Resistance to CDK4/6 Blockade in Advanced Hormone Receptor–positive, HER2-negative Breast Cancer and Emerging Therapeutic Opportunities READ MORE CDK4 and CDK6 kinases: From basic science to cancer therapy READ MORE Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03) READ MORE Phase I/II Trial of Exemestane, Ribociclib, and Everolimus in Women with HR+/HER2− Advanced Breast Cancer after Progression on CDK4/6 Inhibitors (TRINITI-1) READ MORE Endocrine Treatment and Targeted Therapy for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer: ASCO Guideline Update READ MORE The role of CDK4/6 inhibitors in early breast cancer READ MORE Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer—The Penelope-B Trial READ MORE CDK4/6 inhibition in early-stage breast cancer: how far is it from becoming standard of care? READ MORE Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study READ MORE Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study READ MORE Inhibiting CDK4/6 in Breast Cancer with Palbociclib, Ribociclib, and Abemaciclib: Similarities and Differences READ MORE Cyclin-dependent kinase 4/6 inhibitors and interstitial lung disease in the FDA adverse event reporting system: a pharmacovigilance assessment READ MORE Management of Abemaciclib‐Associated Adverse Events in Patients with Hormone Receptor‐Positive, Human Epidermal Growth Factor Receptor 2‐Negative Advanced Breast Cancer: Safety Analysis of MONARCH 2 and MONARCH 3 READ MORE 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) READ MORE Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2−, Node-Positive, High-Risk, Early Breast Cancer (monarchE) READ MORE Comparison of treatment-related adverse events of different Cyclin-dependent kinase 4/6 inhibitors in metastatic breast cancer: A network meta-analysis READ MORE Health-related quality of life in premenopausal women with hormone-receptor-positive, HER2-negative advanced breast cancer treated with ribociclib plus endocrine therapy: results from a phase III randomized clinical trial (MONALEESA-7) READ MORE Health‐Related Quality of Life in MONARCH 3: Abemaciclib plus an Aromatase Inhibitor as Initial Therapy in HR+, HER2− Advanced Breast Cancer READ MORE Intrinsic and acquired resistance to CDK4/6 inhibitors and potential overcoming strategies READ MORE Overall Survival of CDK4/6-Inhibitor–Based Treatments in Clinically Relevant Subgroups of Metastatic Breast Cancer: Systematic Review and Meta-Analysis READ MORE Mechanisms of Sensitivity and Resistance to CDK4/6 Inhibition READ MORE Hematologic adverse events following palbociclib dose reduction in patients with hormone receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer: pooled analysis from randomized phase 2 and 3 studies READ MORE Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future READ MORE Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer READ MORE PTEN Loss Mediates Clinical Cross-Resistance to CDK4/6 and PI3Kα Inhibitors in Breast Cancer READ MORE The Ongoing Search for Biomarkers of CDK4/6 Inhibitor Responsiveness in Breast Cancer READ MORE CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis READ MORE Health‐Related Quality of Life in MONARCH 2: Abemaciclib plus Fulvestrant in Hormone Receptor‐Positive, HER2‐Negative Advanced Breast Cancer After Endocrine Therapy READ MORE Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up READ MORE Facebook Twitter Linkedin
